Skip to main content
رجوع
HLUBF logo

H. Lundbeck A/S

جودة البيانات: 100%
ذروة بيع
HLUBF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 4.82
KWD 0.00 (0.00%)
القيمة السوقية: 4.78B
مُدرج أيضًا باسم HLBBF OTC
نطاق اليوم
KWD 4.82 KWD 5.37
نطاق 52 أسبوعًا
KWD 3.67 KWD 6.41
حجم التداول
1
متوسط 50 يوم / 200 يوم
KWD 5.61 / KWD 5.13
الإغلاق السابق
KWD 4.82

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 1.5 0.4
P/B 0.2 2.9
ROE % 12.8 3.7
Net Margin % 13.1 3.9
Rev Growth 5Y % 10.5 10.0
D/E 0.5 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.000
KWD 0.000 – KWD 0.000
26 B 0
FY2026 KWD 0.000
KWD 0.000 – KWD 0.000
25 B 0

النقاط الرئيسية

Revenue grew 10.50% annually over 5 years — strong growth
ROE of 12.78% — decent returns on equity
Debt/Equity of 0.48 — conservative balance sheet
Generating 4.33B in free cash flow
P/E of 1.50 — trading at a low valuation
Cash machine — converts 136.09% of earnings into free cash flow

النمو

Revenue Growth (5Y)
10.50%
Revenue (1Y)10.42%
Earnings (1Y)1.33%
FCF Growth (3Y)10.05%

الجودة

Return on Equity
12.78%
ROIC12.87%
Net Margin13.11%
Op. Margin26.05%

الأمان

Debt / Equity
0.48
Current Ratio1.44
Interest Coverage11.72

التقييم

P/E Ratio
1.50
P/B Ratio0.19
EV/EBITDA2.11
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.42% Revenue Growth (3Y) 10.46%
Earnings Growth (1Y) 1.33% Earnings Growth (3Y) 17.93%
Revenue Growth (5Y) 10.50% Earnings Growth (5Y) 24.68%
Profitability
Revenue (TTM) 24.30B Net Income (TTM) 3.18B
ROE 12.78% ROA 5.91%
Gross Margin 79.58% Operating Margin 26.05%
Net Margin 13.11% Free Cash Flow (TTM) 4.33B
ROIC 12.87% FCF Growth (3Y) 10.05%
Safety
Debt / Equity 0.48 Current Ratio 1.44
Interest Coverage 11.72 Dividend Yield 0.03%
Valuation
P/E Ratio 1.50 P/B Ratio 0.19
P/S Ratio 0.20 PEG Ratio 8.40
EV/EBITDA 2.11 Dividend Yield 0.03%
Market Cap 4.78B Enterprise Value 13.37B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 24.30B 22.00B 19.91B 18.25B 16.30B
Net Income 3.18B 3.14B 2.29B 1.92B 1.32B
EPS (Diluted) 3.21 3.17 2.31 1.93 1.33
Gross Profit 19.33B 17.77B 15.43B 14.30B 12.65B
Operating Income 6.33B 3.27B 3.20B 2.85B 2.01B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 53.89B 56.98B 37.41B 37.45B 34.65B
Total Liabilities 29.04B 31.97B 15.36B 16.67B 16.37B
Shareholders' Equity 24.85B 25.01B 22.05B 20.78B 18.28B
Total Debt 12.02B 16.69B 4.15B 5.58B 5.32B
Cash & Equivalents 3.43B 4.66B 5.01B 3.42B 2.28B
Current Assets 12.75B 13.01B 13.29B 11.41B 8.61B
Current Liabilities 8.83B 8.58B 7.99B 8.20B 8.82B

درجات الاستراتيجيات

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
#169 of 1024
64
#376 of 820
44
#438 of 616
21

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026